BeyondSpring Inc

BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing and selling therapies for oncology and immunology. It operates through two segments: the Plinabulin pipeline and the TPD platform. Its lead asset, Plinabulin, is a selective immunomodulating microtubule-binding agent that has completed Phase III trials for non-small cell lung cancer (NSCLC) and is also being developed for the prevention of chemotherapy-induced neutropenia (CIN). The company is also developing Plinabulin in combination with other agents, including nivolumab, ipilimumab, and pembrolizumab, as well as three preclinical small-molecule immune agents and a drug discovery platform. Founded in 2010, it is headquartered in Florham Park, New Jersey.